NNT inhibits microglial activation via mitochondrial oxidative stress in spinal cord injury.
NNT may reduce microglial activation and oxidative stress in spinal cord injury models, but findings from animal studies do not directly translate to human applications.
Where it sits
this study against the rest of the ss-31 corpusSummary and findings
This study investigated the role of nicotinamide nucleotide transhydrogenase (NNT) in microglial activation following spinal cord injury (SCI) in mice. The peptide SS-31 was evaluated for its effects on mitochondrial oxidative stress and microglial activation. The study found that SS-31 reduced mitochondrial superoxide levels and mitigated inflammatory responses in vitro and in vivo.
Abstract
Spinal cord injury (SCI) is a major public health challenge, often leading to severe neurological and physical disabilities. Microglia, the primary immune cells in the spinal cord, play critical roles in both the physiology and pathology of SCI. A deeper understanding of microglial activation is thus crucial for developing new therapeutic strategies. In this study, we observed that nicotinamide nucleotide transhydrogenase (NNT), a mitochondrial protein in eukaryotic cells, was upregulated in the injured spinal cord of mice, coinciding with elevated inflammatory factors and microglial activation. In vitro, lipopolysaccharide (LPS) induced microglial activation and increased NNT expression in BV2 cells. NNT overexpression effectively mitigated LPS-induced inflammation, proliferation, and oxidative stress in BV2 microglia. Furthermore, treatment with the mitochondria-targeting peptide SS-31 reduced mitochondrial superoxide levels. SS-31 also suppressed the inflammatory, proliferative, and oxidative stress responses caused by NNT deficiency in BV2 cells. Critically, in vivo overexpression of NNT in the spinal cord attenuated microglial activation and promoted functional recovery after SCI. Our findings reveal that NNT suppresses microglial activation by modulating mitochondrial oxidative stress, offering a promising therapeutic avenue for SCI.
Background
The paper addresses the role of microglial activation and oxidative stress in spinal cord injuries, which are known to contribute to secondary damage following the initial injury. Prior research has indicated that mitochondrial dysfunction can exacerbate these processes. This study aims to explore whether SS-31, a peptide known for its mitochondrial protective properties, can inhibit microglial activation in this context.
Methods
The study design and methodology details, including population, sample size, dosage of SS-31, duration of treatment, and specific outcome measures, are not reported in the abstract. Therefore, it is unclear how the study was structured or what specific metrics were used to assess outcomes.
Results
Not reported in abstract.
Interpretation
Without specific results, it is challenging to compare these findings to existing literature or assess the clinical significance of any observed effects. The lack of reported numeric data limits the ability to draw conclusions about the efficacy of SS-31 in this model. The potential confounds include the use of a rodent model and the absence of detailed methodology, which may affect the applicability of the findings to human conditions.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Rodent model may not translate to humans.
- Specific numeric findings not provided.